As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...

The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with T2D.

Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.

Novo Nordisk's SOUL trial reveals a 14% reduction in major cardiovascular events with oral semaglutide in patients with type ...

The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard ...

The Wegovy makers’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in ...

The pill version of Novo Nordisk’s (NVO) blockbuster drug Ozempic was found to cut the risk of heart attacks, strokes, and ...

Discover how Novo Nordisk's GLP-1 medication, Rybelsus, reduces major adverse cardiovascular events by 14% in a phase 3 trial, with plans for an expanded label.

Semaglutide and tirzepatide helped Texas woman Kathryn Dean lose 18kg and keep the weight off, and she is no longer diagnosed ...

Novo expects to file for a label expansion for Rybelsus in the United States and the European Union around the turn of the ...

The Russian leader hopes to use the meeting of the so-called BRICS group, which includes China and India, as a counterweight to the West. By Valerie Hopkins and David Pierson The former U.S ...

Inside the Last-Ditch Hunt by Harris and Trump for Undecided Voters Both campaigns think many of these crucial Americans are younger, Black or Latino. The Harris team is also eyeing white, college ...